Epigenetic Mechanisms in Osteoporosis: Exploring the Power of m 6 A RNA Modification
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70344 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Shuo Tian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, China. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Osteoporosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Scientific and Technological Project of Henan Province, Key Scientific Research Projects of Colleges and Universities of Henan Province, Specialized Scientific Research on Medical Science in the Double First-class Founding Disciplines of Henan Province in 2023.
Abstract (Originalsprache)
Osteoporosis, recognised as a metabolic disorder, has emerged as a significant burden on global health. Although available treatments have made considerable advancements, they remain inadequately addressed. In recent years, the role of epigenetic mechanisms in skeletal disorders has garnered substantial attention, particularly concerning m 6 A RNA modification. m 6 A is the most prevalent dynamic and reversible modification in eukaryotes, mediating various metabolic processes of mRNAs, including splicing, structural conversion, translation, translocation and degradation and serves as a crucial component of epigenetic modification. Research has increasingly validated that m 6 A plays a vital role in the proliferation, differentiation, migration, invasion,and repair of bone marrow mesenchymal stem cells (BMSCs), osteoblasts and osteoclasts, all of which impact the whole process of osteoporosis pathogenesis. Continuous efforts have been made to target m 6 A regulators and natural products derived from traditional medicine, which exhibit multiple biological activities such as anti‐inflammatory and anticancer effects, have emerged as a valuable resources for m 6 A drug discovery. This paper elaborates on m 6 A methylation and its regulatory role in osteoporosis, emphasising its implications for diagnosis and treatment, thereby providing theoretical references.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
- Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao, Zhengzhou, China.
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, China.
ORCID-Profile: Shuo Tian
Förderung
- Key Scientific and Technological Project of Henan Province
- Key Scientific Research Projects of Colleges and Universities of Henan Province
- Specialized Scientific Research on Medical Science in the Double First-class Founding Disciplines of Henan Province in 2023
- Henan Provincial Science and Technology R&D Plan Joint Fund (Advantageous Discipline Cultivation Category) Project
- National Natural Science Foundation of China - State Grid Corporation Joint Fund for Smart Grid
- Henan Province Youth Talent Promotion Project
- Henan Provincial Key R&D Program
Zitieren
APA
Tian, S., Song, Y., Guo, L., Zhao, H., Bai, M., & Miao, M. (2025). Epigenetic Mechanisms in Osteoporosis: Exploring the Power of m 6 A RNA Modification. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70344
Vancouver
Tian S, Song Y, Guo L, Zhao H, Bai M, Miao M. Epigenetic Mechanisms in Osteoporosis: Exploring the Power of m 6 A RNA Modification. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70344
BibTeX
@article{Tian2025,
author = {Tian, Shuo and Song, Yagang and Guo, Lin and Zhao, Hui and Bai, Ming and Miao, Mingsan},
title = {Epigenetic Mechanisms in Osteoporosis: Exploring the Power of m 6 A RNA Modification},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70344}
}
EUVIMED